Stephen Davis
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Stephen Davis
Stephen Davis was last confirmed as CEO and Board Member at Acadia Pharmaceuticals Inc (ACAD) in a filing dated April 26, 2024. The proxy statement of Acadia Pharmaceuticals Inc reports total compensation of $14,028,139 for Stephen Davis in fiscal 2022, including a base salary of $822,316. Disclosed compensation is on record for 5 fiscal years. Stephen Davis has spoken on 8 earnings calls across 1 company, most recently for Acadia Pharmaceuticals Inc on November 2, 2022.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Start not stated–2024-04-26
Last confirmed by a filing; no departure on record
-
Start not stated–2024-04-26
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Acadia Pharmaceuticals Inc (ACAD) | — | $822,316 | $14,028,139 |
| 2021 | Acadia Pharmaceuticals Inc (ACAD) | — | $792,831 | $9,793,289 |
| 2020 | Acadia Pharmaceuticals Inc (ACAD) | — | $767,624 | $7,763,187 |
| 2019 | Acadia Pharmaceuticals Inc (ACAD) | — | $743,705 | $7,631,245 |
| 2018 | Acadia Pharmaceuticals Inc (ACAD) | — | $719,833 | $6,508,032 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.